About Mend
Mend serves people preparing for surgery, recovering from injury, managing weight or seeking everyday health support. It combines nutrition formulas with coaching and care delivered from a distance. Products include Joint Replacement, Repair + Recover and Regenerate. The Upgraid program adds monitoring and behavior-change support. Its Ignite path focuses on surgical readiness and lasting weight loss. Nourished provides more intensive coaching for people whose weight is delaying surgery.
Founded and headquartered in New York City, Mend was located at BioLabs at NYU Langone in 2023. Paul Roscoe is CEO and has more than 25 years of experience across digital health, software services and data-driven healthcare. Co-founder Eziah Syed previously held senior strategy roles at Deloitte and Citibank. VitalityHealth partnered with Mend to address age-related muscle loss at six Southwest clinics. Mend products have also been adopted by numerous hospitals, professional sports teams across major leagues and elite U.S. military units.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 9, 2026 | Oct 19, 2026 | $1,500,000of $3.0M target | 3 | $500K | Equity, DebtRule 506(b) | Form D ↗ |
| Feb 5, 2026 | Feb 11, 2026 | $9,857,101of $12.0M target | 18 | $547K | EquityRule 506(b) | Form D ↗ |
| Jun 11, 2025 | Jun 25, 2025amended Dec 4, 2025 | $3,937,500of $5.0M target | 8 | $492K | Equity, DebtRule 506(b) | Form D/A ↗3 earlier filings |
| Apr 24, 2023 | Apr 24, 2023amended Aug 19, 2024 | $16,540,843of $17.2M target | 16 | $1.0M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Jan 29, 2022 | Aug 30, 2022 | $2,998,552of $3.0M target | 22 | $136K | Equity, DebtRule 506(b) | Form D ↗ |
| Not yet | Dec 16, 2020 | $0of $5.0M target | 0 | — | EquityRule 506(b) | Form D ↗ |
| Dec 9, 2018 | Jun 4, 2020 | $745,000of $1.5M target | 18 | $41,389 | Debt, Convertible NoteRule 506(b) | Form D ↗ |
| Dec 9, 2018 | Jul 3, 2019amended Mar 11, 2020 | $630,000of $1.5M target | 15 | $42,000 | DebtRule 506(b) | Form D/A ↗1 earlier filing |
| Total, eight offerings | $36,208,996 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by Mend
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Dec 11, 2025 | Series A | $20 million | Crain's New York Business ↗ | |
| Jun 6, 2023 | Series A | $15 million | S2G Ventures (lead), iSelect Fund, Touchdown Ventures, Colorcon Ventures, Keen Growth Capital, Genhen Capital and Alumni Ventures | Mend Series A announcement ↗ |
Why Investors Backed Mend
Mend sells clinical nutrition and remote care for recovery and longer-term health. Its model combines physical formulas with programs delivered through medical providers. Surgery is the main entry point. Its programs also cover weight management and everyday wellness.
The problem it targets
Patients can reach surgery with poor nutrition or obesity, then face delays without enough guidance. Mend targets people told to lose weight or change their diet but lacking tools and support. Mend views surgery as a moment when patients are highly engaged and open to lasting behavior change.
What the product does
Upgraid places nutrition protocols, real-time remote monitoring and behavioral coaching inside clinical workflows. Registered dietitians and care navigators support patients through a digital program. AI-generated insights augment the care process. Ignite emphasizes surgical readiness, inflammation control, muscle preservation and behavior change. Nourished adds intensive coaching, supplements and monitoring for patients whose weight delays surgery.
Progress so far
Platform users include Geisinger, OrthoLoneStar and the U.S. Department of Defense. More than 1,000 patients received Mend products through orthopedic surgeon Robert Marx. Regenerate received an Anti-Aging Product of the Year award. Among Upgraid participants, 93% rated the program better than their previous healthcare experiences.
Who backs it
S2G tied its support to bridging natural approaches and mainstream medicine. Dan Ripma, a vice president at S2G Ventures, also emphasized improved patient care and lower provider stress. S2G based its decision on Mend's ability to address urgent health-system needs.
How the market is moving
A survey of more than 1,300 patients found that 93% wanted their doctor to guide nutrition and recovery. Mend interprets that result as demand for broader support around surgery. It also sees obesity-related surgical delays as a recurring problem for providers.
We wrote this summary from public statements by Mend and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Mend's Form D filed Oct 19, 2026.
Earlier filings also listed Eziah Syed (executive officer and director, last listed Dec 2025), Justin Kamine (director, last listed Aug 2024), Helene Rutledge (executive officer and director, last listed Aug 2022) and Chris Gusty (executive officer, last listed Aug 2022).
Sources
- SECMEND NUTRITION INC. Form D/A, filed Oct 17, 2025
- SECMEND NUTRITION INC. Form D/A, filed Aug 20, 2025
- SECMEND NUTRITION INC. Form D, filed Jun 25, 2025
- SECMEND NUTRITION INC. Form D, filed Apr 24, 2023
- SECMEND NUTRITION INC. Form D, filed Jul 3, 2019
- SECMEND NUTRITION INC. filing history
- CompanyMend privacy policy
- CompanyAbout Mend
- PressMend Upgraid expansion announcement
- CompanyMend and VitalityHealth partnership